We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Udg Healthcare Public Limited Company | UDG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1,079.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1,079.00 | 1,079.00 |
| Top Posts |
|---|
Posted at 30/5/2021 09:17 by carcosa FT:M&G Investments, the £367bn asset manager, has blasted plans to sell London-listed UDG Healthcare to buyout firm Clayton, Dubilier & Rice, the latest in a series of criticisms of private equity deals by big fund managers. Shareholders are due to vote in June on the £2.8bn all-cash offer to sell UDG, which provides clinical, commercial, communication and packaging services for the healthcare industry. But London-based M&G, which is a top-five shareholder in UDG according to data provider CapitalIQ, said the bid “fails to offer fair value to ordinary shareholders, including the customers on whose behalf we invest”. Allianz Global Investors, UDG’s largest shareholder, has also criticised the deal. Earlier this month, Elliott Investment Management, the activist investor, said it had taken a stake in the Dublin-headquartered company. The criticism by M&G and AllianzGI comes at a time of growing concern in the UK that listed companies are being sold off too cheaply to private equity firms. While fund managers rarely make public statements on companies, some have decided to speak out about deals involving private equity in recent weeks, including Schroders, which criticised transport operator FirstGroup’s planned £3.3bn sale of its US business to Swedish buyout group EQT. Private equity groups, many of which have raised their largest-ever funds, are targeting the UK stock market with the aim of capitalising on lower valuations in the wake of Brexit and the pandemic. Thirteen private equity buyouts of UK-listed companies have been announced since the beginning of 2021, the highest year-to-date figure since 2006, according to figures from Refinitiv. Just two were announced during the same period in 2019. Rory Alexander, a fund manager at M&G, said he was concerned that CD&R would benefit from the UDG deal at the expense of ordinary investors. “The $3.7bn offer does not reflect the potential long term value creation of UDG’s organic growth story, opportunity for strategic acquisitions, consistent cash generation and fortress balance sheet,” he said. “The material mismatch between the offer price and our opinion of UDG’s true value represents upside transferred away from ordinary shareholders towards the private equity bidder.” UDG declined to comment. But when the deal was announced on May 12, UDG chair Shane Cooke, said it was an “attractive offer”. He added that it “secures the delivery of future value for shareholders in cash today. The offer reflects the quality, strength and long term performance of UDG’s businesses and its future growth potential”. CD&R declined to comment. AllianzGI, which owns 8.6 per cent of UDG’s shares, said earlier this month that the price did “not adequately compensate existing shareholders”, adding that it was the duty of the board to “obtain a fair value for shareholders”. “AllianzGI firmly believes that the offer is opportunistic and significantly undervalues UDG and its prospects and is not in the best interests of shareholders. Consequently, based on available information, AllianzGI is minded not to accept the current offer despite it being recommended to shareholders by the Board of UDG,” it added. |
Posted at 09/10/2007 12:38 by johnnyad I suppose that will depend on UDG maintaining their discount % to the standard/new rate liars.UDG's figures speak for themselves and I hope they maintain their margins at the same level. It's about time this share got recognised for the quality and potential it clearly has for the long term investor. AIMHO of course. |
Posted at 14/11/2006 17:47 by what is a login ? Thanks Liarspoker. I eventually found myself here via United Carpets and United Utilities. As different as chalk and cheese. I wanted to buy into this one at 250 for simplicity of monitoring but Selftrade screwed up and were unable to confirm the trade. By the time I phoned London for explanations the UDG share price had inexplicably gone up to nearly 254! The only thread I really have time for is the ANGL thread. I have learnt many things there. The thread of the discerning investor. From time to time I see what's going on at SOLA. |
Posted at 08/11/2006 00:12 by slasher16 Hi Liarspoker, Mes a Tipp guy only 24 over year out of college. Was at Mahon point shopping centre there recently so i do know Cork. Bought united drug with my savings in colege a year and a have ago as a long term investment. Could prove a good investment long term with demographics and everything. I really thought they were a lifer given my skipping of lectures and reading many books on stocks and shares in the waterford IT libary. However this govt decision is having a serious impact on stock sentiment or are u sayin its goin to hit earnings for a couple of years goin foward? EPS in interims was 14% and is expected to be 12% for year ahead. Maybe the lesson here is to buy unregulated companies with higher profit margins? Any views experienced investor? |
Posted at 18/9/2006 08:08 by liarspoker Notice of ResultsUnited Drug plc Dublin: UDG.I London: UDG.L 2006 Full Year Trading Statement Dublin, September 15, 2006: United Drug plc ("UD" or the "Group"), a leading provider of services to pharmaceutical retailers and manufacturers in Ireland and the UK, today confirmed that it will issue a trading statement, for the 12 months ending September 30, 2006, at 7.00am (GMT) on Thursday, October 5, 2006. The Group will announce 2006 full year results on November 22, 2006 at 7.00am (GMT). For further details, please contact K Capital Source on +353 1 6315500 or UnitedDrug@kcapitals About United Drug plc United Drug is a leading provider of services to pharmaceutical retailers and manufacturers. It is the largest pharmaceutical wholesaler in the island of Ireland. UD is also the market leader in contract distribution outsourcing (pre-wholesaling) in Ireland and has achieved the No. 1 position in the UK through its joint venture business UniDrug Distribution (UDG). In addition to contract distribution services for pharma manufacturers, United Drug provides contract distribution, sales & marketing and technical services to Medical & Scientific equipment & consumable manufacturers, with a market leading position in Ireland and an emerging presence in the UK. United Drug is also leading provider of contract sales outsourcing services to pharmaceutical manufacturers in the UK and Ireland. Investors and analysts Media -------------------- |
Posted at 11/9/2006 16:12 by liarspoker The company is the same value now as +- 2 years ago. The market is innefficient alright, much to the delight of us investors. :O)Just remember 80% of the people make their money 20% of the time. Another leg up is not too far away. |
Posted at 29/11/2004 12:39 by m.t.glass "...likely to lead to big earnings upgrades in the coming weeks..."The Times: ShareWatch: United Drug continues on a high EDITED BY FRANK FITZGIBBON THESE are good times for investors in United Drug who have enjoyed almost two years of uninterrupted growth in the share price during which time the company’s market value has soared to €745m. Last week’s results were excellent. The biggest surprise came in the form of improved margins. Given the low returns that distinguish this distribution business that was no mean feat and is likely to lead to big earnings upgrades in the coming weeks. Davy Stockbrokers notes that most of United Drug’s key capital commitments are almost complete. It says that in coming years a larger proportion of EBITDA (earnings before interest, tax, depreciation and amortisation) will translate to free cash flow, “enabling rapid run-down of debt and strengthening of balance-sheet finances”. United Drug’s organic growth prospects can be supplemented by acquisitions without adversely stretching the balance sheet. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
